Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Lyv Sciences Co. Ltd. operates a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. There are currently 2 pending office actions associated with this portfolio. These matters are spread across 2 distinct examiners and 2 distinct art units. This variety suggests that the company's Biotechnology & Pharmaceuticals applications cover different technical aspects that fall under the jurisdiction of separate examination teams. The use of 2 distinct art units provides a more diversified prosecution landscape than a portfolio limited to 1 distinct art unit.
CRAIGO, BAHAR ALAWI is the busiest examiner for the company, overseeing 1 busiest examiner pending office action. Because there are 2 pending office actions in total, this examiner is responsible for the 1 busiest examiner pending office action. The involvement of 2 distinct examiners suggests that the company's technology is being reviewed by multiple specialized teams. This diversification can be beneficial, as it prevents the pending portfolio from being subject to the potential delays of a single art unit. Practitioners should coordinate their responses to ensure consistency across the 2 pending office actions.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| CRAIGO, BAHAR ALAWI | 1 | 47.1% | +27.3% |
| YU, HONG | 1 | 30.9% | +5.6% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18260065 | CROSSLINKED HYALURONIC ACID HYDROGEL CROSSLINKED USING CROSSLINKER AND POLYOL, AND FILLER COMPRISING SAME | CRAIGO, BAHAR ALAWI | — |
| Art Unit | Apps |
|---|---|
| 1699 | 1 |
| 1614 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18260065 | CROSSLINKED HYALURONIC ACID HYDROGEL CROSSLINKED USING CROSSLINKER AND POLYOL, AND FILLER COMPRISING SAME | CRAIGO, BAHAR ALAWI | 1699 | §103 | Final Rejection | — | Pending | Jun 30, 2023 |
| 17258400 | HYALURONIC ACID FILLER HAVING HIGH LIFT CAPACITY AND LOW INJECTION FORCE | YU, HONG | 1614 | §103 | Final Rejection | 59d overdue | Pending | Jan 06, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial